GLP-1 Receptor Agonists May Reduce Obesity-Associated Cancer Risk in Nondiabetic Adults: Annals of Oncology | August 2026

Introduction:

Obesity is a major risk factor for at least 13 obesity-associated cancers (OACs), and its global prevalence continues to rise. With the increasing use of GLP-1 receptor agonists (GLP-1RAs) for weight management in individuals without diabetes, an important question has emerged: Can these agents also reduce cancer risk? This large real-world study evaluated the association between GLP-1RA therapy and the incidence of obesity-related cancers in obese adults without diabetes.

Why was this study needed?

Obesity is a well-established risk factor for multiple cancers.

GLP-1 receptor agonists are increasingly prescribed for obesity in nondiabetic individuals.

Previous studies largely involved patients with diabetes, making it difficult to separate the effects of glucose control from weight loss.

Whether GLP-1RAs reduce cancer risk in obese patients without diabetes has remained unknown.

Understanding this association could influence long-term obesity management strategies.

Results:

This large target trial emulation included over 229,000 obese adults without diabetes, making it the first study focused exclusively on this population.

After matching for baseline characteristics, GLP-1RA users had a significantly lower incidence of obesity-associated cancers compared with patients managed with diet and exercise counselling alone.

The reduction in cancer risk was observed after a median follow-up of two years.

The association remained consistent across both semaglutide and tirzepatide, as well as across most sex and BMI subgroups.

The protective association was not consistently observed among Black patients, highlighting the need for further investigation into potential biological or socioeconomic differences.

Multiple sensitivity analyses confirmed the robustness of the findings.

Clinical Impact:

This study provides the strongest evidence to date that GLP-1 receptor agonists may offer benefits beyond weight reduction, potentially lowering the short-term risk of obesity-associated cancers in nondiabetic individuals. While the mechanism remains uncertain—whether mediated by weight loss, metabolic improvement, anti-inflammatory effects, or direct antitumor activity—the findings add to the growing body of evidence supporting the broader health benefits of GLP-1RAs. However, because this was an observational study with relatively short follow-up, the results should not yet be interpreted as proof of cancer prevention.

Bottom Line:

Among obese adults without diabetes, GLP-1 receptor agonist therapy was associated with a significantly lower short-term incidence of obesity-associated cancers compared with lifestyle counselling alone. Although these findings are encouraging, prospective randomised studies with longer follow-up are needed before GLP-1RAs can be recommended as a strategy for cancer prevention.